Alnylam Pharmaceuticals (ALNY) Stock Looks Pricey Despite A 51% Slide

Alnylam Pharmaceuticals has seen a steep share price reset over the past year, which puts the focus squarely on whether the current valuation lines up with what the business earns. With recent legal scrutiny adding another layer of uncertainty, the key issue for investors is how much of that risk and opportunity is already reflected in the stock. The share price has fallen 50.9% over the past year, which raises the question of whether the current level now better reflects the company’s...